All In Biotech

Drug Trial Radar · NCT05819658

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase IIa Exploratory Clinical Trial to Evaluate the Efficacy and Safety of SC Administration of GV1001 0.56 or 1.12 mg/Day in Patients With PSP

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Jun 14, 2023

Primary completion

Oct 11, 2024

Study completion Oct 11, 2024

Sponsor

Lead sponsor
GemVax & KaelIndustry
Sponsor type
Industry
First posted
Apr 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 41 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP). In 75 patients diagnosed with PSPR Richardson(PSP-RS) or PSP-Parkinsonism (PSP-P) at five hospitals in Korea, subcutaneous administration of GV1001 0.56 or 1.12 mg/day will be conducted with multicenter, randomized, double-blind, placebo-controlled, parallel design, prospective phase 2a.

Conditions

  • Progressive Supranuclear Palsy

Interventions

  • GV1001 PlaceboDrug

    0.9% normal saline

  • GV1001 0.56mgDrug

    Lyophilized peptide from hTERT

  • GV1001 1.12mgDrug

    Lyophilized peptide from hTERT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From the Baseline in the Total Score of PSP-rating ScaleTime frame: 24 weeks(6 months)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Kyung Hee University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul Metropolitan Government Seoul National University Boramae Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.